43 results about "Quercetin Glycoside" patented technology

The invention discloses application of heat-resistant beta-glucosidase and mutants thereof. The mutants of the heat-resistant beta-glucosidase G224T, N223S and N223S / G224T have the amino acid sequences shown in SEQ: ID NO. 1, SEQ: ID NO. 2 and SEQ: ID NO. 3; the heat-resistant beta-glucosidase and the mutants thereof can be used for preparing quercetin through enzymolysis of quercetin glycoside. The preparation of the quercetin through the heat-resistant beta-glucosidase and the mutants thereof has the advantages of high conversion efficiency, few reaction byproducts, easy separation and purification of the product, less chemical pollution, and high yield and high purity of the obtained quercetin product, and the like.

The present invention provides an +--glycosyl isoquercitrin-containing novel composition which has a high in vivo absorbability, and hence exhibits a significant in vivo antioxidative activity. The present invention further provides preparation methods for such a composition. The composition contains a mixture of quercetin glycosides represented by the following formula: wherein Glc represents a glucose residue, and n is 0 or a positive integer of 1 or more, includes at least a quercetin glycoside wherein n is 3, and satisfies the following requirement (a): (a) the total proportion of quercetin glycosides in which n is 3, and in which other n values may be 1 or 2, or 1 and 2, is 50 mol% or more, and the total proportion of quercetin glycosides wherein n is 4 or more is 15 mol% or less, in the composition. The composition can be prepared by treating an enzymatically modified isoquercitrin with -amylase.

The invention discloses an application of a folium eucalypti extractive serving as an active ingredient in preparation of medicines for treating hyperuricemia, and also provides a preparation method of the folium eucalypti extractive. Main active ingredients of the folium eucalypti extractive are 6-12% of scabish essence B, 1-2% of tellimagrandin I, 1-1.5% of quercetin-3-O-glucoside acid, 0.8-1.2% of ellagic acid, 0.2-0.5% of tellimagrandin II, 0.1-0.15% of 1,2,3,4,6 pentagalloylglucose and 25-50% of total phenols. The pharmacological experiment shows that the folium eucalypti extractive has an inhibiting effect on xanthine oxidase and relatively strong effects of reducing uric acid, protecting renal injury caused by the hyperuricemia and the like in bodies.

The invention provides a bauhinia championii acetic ether extract, which comprises not less than 0.05 percent by weight of quercetin glycoside and not less than 0.04 percent by weight of myricetin. The invention further provides a preparation method and an application of the bauhinia championii acetic ether extract. The invention further provides a bauhinia championii n-butyl alcohol extract, which comprises not less than 0.1 percent by weight of beta-sitosterol. The invention further provides a preparation method and an application of the bauhinia championii n-butyl alcohol extract. A bauhinia championii acetic ether part and an n-butyl alcohol part are used for treating rheumatoid arthritis, and have definite medicinal effects and controllable quality; moreover, the preparation methods are stable, and are suitable for mass production; and a novel option is provided for clinical treatment.

The purpose of the present invention is to provide a novel muscle atrophy inhibitor containing an ingredient that can be taken safely over an extended period of time. It was discovered that a glycoside of quercetin, which is a type of polyphenol contained in plants and the like, has an inhibitory effect on the expression of myostatin which is involved in muscle atrophy. The present invention provides a novel muscle atrophy inhibitor containing quercetin glycoside, the muscle atrophy inhibitor having exceptional bioavailability and high safety.

The present invention relates to the technical field of health products and particularly relates to a tablet containing EGCG (epigallocatechin gallate). The tablet is a compound preparation including the EGCG and quercetin or quercetin glycoside derivatives. A ratio of the EGCG to the quercetin or quercetin glycoside derivatives is (3-8):(0.3-1). In the tablet, the EGCG and quercetin or quercetin glycoside derivatives are prepared into the compound preparation. The materials are synergistically and mutually promoted, and especially, absorptions of the quercetin or quercetin glycoside derivatives are promoted. At the same time, by adding resveratrol and sorbitol in the tablet, absorption efficiencies and absorption rates of the EGCG are improved.

The invention relates to a juglans mandshurica husk extractive which contains the main medical active ingredients of 8-hydroxyl-9,10-anthraquinone-1-carboxylic acid, REG IOLONE, 4,5,8- trihydroxy-alpha-naphthyl ketone-3-O-beta-D-glucopyranoside, 4,5,8- trihydroxy-alpha- naphthyl ketone-3-O-(6'-O- nutgall acyl)-beta-D- glucopyranoside, 1-(4'- hydroxyl phenyl)-7-(3''-methoxy-4''-hydroxyl phenyl) heptane-3-alcohol, 4-hydroxy-2,6- syringol-1-O-beta-D-glucopyranoside, 4- hydroxyl-2,6- syringol-1-O-(6'-O- nutgall acyl)-beta-D- glucopyranoside, vanillic acid-4-O-(6'-O- nutgall acyl)-beta-D-glucopyranoside, vanillic aldehyde, vanillic acid, gallic acid, syringic acid, kaempferol, quercetin glycoside, myrica rubra and quercetin. The juglans mandshurica husk extractive has good effect in curing hepatopathy and restraining the growth of tumor and especially has the effect of directly killing the hepatocarcinoma cells.

The invention discloses application of heat-resistant beta-glucosidase and mutants thereof. The mutants of the heat-resistant beta-glucosidase G224T, N223S and N223S / G224T have the amino acid sequences shown in SEQ: ID NO. 1, SEQ: ID NO. 2 and SEQ: ID NO. 3; the heat-resistant beta-glucosidase and the mutants thereof can be used for preparing quercetin through enzymolysis of quercetin glycoside. The preparation of the quercetin through the heat-resistant beta-glucosidase and the mutants thereof has the advantages of high conversion efficiency, few reaction byproducts, easy separation and purification of the product, less chemical pollution, and high yield and high purity of the obtained quercetin product, and the like.

The invention discloses a preparation method of oriental cherry powder with activity of inhibiting generation of AGE. The method comprises low-temperature processes of cleaning, countercurrent extraction, filtration, concentration, sterilization, freeze drying, sieving and the like. Countercurrent extraction and low-temperature membrane treatment are combined for extraction of oriental cherry, and a low-temperature process is adopted in the whole process and totally-closed intensive continuous production is adopted. According to the method, the contents of total flavonoids, caffeoyl glucose (1-O-caffeoyl-beta-D-glucopyranoside) and quercetin glucoside (quercetin-3-O-beta-D-glucopyranoside) contained in the oriental cherry are fully reserved, separated and enriched, active ingredients are fully extracted, the transfer rate is high, the yield of the active ingredients of the prepared oriental cherry powder is high, and the prepared oriental cherry powder is suitable for industrial production. A green membrane material is adopted, the safety is high, and active ingredients are effectively enriched, so that the prepared oriental cherry powder has a remarkable effect of inhibiting the generation activity of AGEs, the generation inhibition rate of AGEs reaches 58% (when the concentration is 100 micrograms per milliliter), and IC50 reaches 67 micrograms per milliliter.

The invention discloses a wikstroemia indica (L.) C.A.Mey extract as well as a preparation method and application thereof. The wikstroemia indica (L.) C.A.Mey extract has the effective compositions of: naringenin, 5, 6, 7- trihydroxy-4'-methoxyflavanone, p-hydroxybenzoic acid, benzoic acid, quercetin glycoside,genkwano1 B, daphnoretin, Lirioresinol, Sikokianin and the like. The invention simultaneously provides application of the wikstroemia indica (L.) C.A.Mey extract, in particular the favorable application in preparing anti-cancer or anti-inflammation analgesia drug. A cytotoxicity experiment shows that the wikstroemia indica (L.) C.A.Mey extract disclosed by the invention has cytotoxicity functions on breast cancer of human, breast cancer drugresistant cell strain, mouse breast adenocarcinoma, which are in linear relation.

The invention provides a bauhinia championii acetic ether extract, which comprises not less than 0.05 percent by weight of quercetin glycoside and not less than 0.04 percent by weight of myricetin. The invention further provides a preparation method and an application of the bauhinia championii acetic ether extract. The invention further provides a bauhinia championii n-butyl alcohol extract, which comprises not less than 0.1 percent by weight of beta-sitosterol. The invention further provides a preparation method and an application of the bauhinia championii n-butyl alcohol extract. A bauhinia championii acetic ether part and an n-butyl alcohol part are used for treating rheumatoid arthritis, and have definite medicinal effects and controllable quality; moreover, the preparation methods are stable, and are suitable for mass production; and a novel option is provided for clinical treatment.

The invention relates to application of quercetin-3'-O-beta-D-glucoside as an inhibitor of calcium ion channels, and belongs to the field of medicine. The invention also provides application of quercetin-3'-O-beta-D-glucoside in preparation of drugs for treating cardiovascular diseases, coronary heart diseases, atherosclerosis, advanced renal failure, neurological diseases, chronic pain, acute pain or inflammatory diseases, and proves that quercetin-3'-O-beta-D-glucoside can inhibit calcium ion channels, especially TRPC ion channels, and the application of the quercetin-3'-O-beta-D-glucoside is expanded.

The invention belongs to the field of analytical chemistry and discloses a high-performance liquid chromatographic analytical method for measuring the content of quercetin-7-glucoside in sorghum red pigment; in the method, octadecylsilane-bonded silica gel is used as a filling agent for a chromatographic column, methanol-acetic acid solution is used as a mobile phase, the content of quercetin-7-glucoside can be quantitatively measured, and the quality of sorghum red pigment is effectively controlled. The method is highly specific and accurate, has good repeatability, and is simple to perform.

A method of reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising administering an effective amount of quercetin-3 β-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier, to said host prior to said exposure.

The present invention discloses a method for improving polarity of flavonoid glycoside reacting flavone aglycon, glucosyltransferase and sugarsubstrate in ethanol water solution with 0-90% thickness. The weight volume ratio of said flavone aglycon and ethanol water solution is 0.03-0.07g / 100ml. said reacting temperature is 20-90 DEG C, the reacting time is 1-30 hours. The invention can apparently improve the water-solubility of flavone aglycon such as quercetin and naphthol, which are easily dissolved by polar solvent such as water or ethanol in industry production, the quercetin glucoside and the naphthol glucoside as medical production, comparing with the quercetin and naphthol, are easily to be used by organism; the invention also can improve the extracting ratio of flavonoid in natural product which reduces the ethanol using quantity in the extracting process; in addition, the invention also can improve the processability of total flavone and pure total flavone product, mean time expand its practical application range.

The invention relates to the field of extraction of natural compounds, in particular to a method for separating flavonoid components in annona squamosa leaves. An ethanol extract of the annona squamosa leaves is subjected to dealcoholization, petroleum ether degreasing and n-butyl alcohol extraction to obtain a crude flavonoid extract, and the crude flavonoid extract is distributed by a two-phasesolvent to obtain a total flavonoid sample. By means of high-speed countercurrent chromatography, a secondary flavonoid extract is separated and purified to obtain quercetin-3-O-beta-D-glucoside, kaempferol-3-O-robinobioside, kaempferol-3-O-rutinoside, quercetin-3-O-robinobioside and rutin, and the purity is 95% or above. The invention further provides a method for separating the flavonoid components through linear elution. High-purity monomer can be obtained, and the method has good popularization significance.